Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Bonomarlot6 residuesAEDRVGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: A-20, Bone Marrow Peptide Bioregulator, Cytomax Bonomarlot
Khavinson's team showed that short peptides (AED, KED, KE) boosted IGF1 expression 3.5 to 5.6-fold in human bone marrow stem cells [1]. Bonomarlot (A-20) is a Cytomax bioregulator extracted from calf bone marrow, designed to deliver those same tissue-specific peptide signals in oral capsule form. No clinical trial has tested Bonomarlot itself in humans. The longevity community uses it in pulsed 10 to 30-day courses, tracking CBC panels rather than expecting a felt response, stacking it alongside Thymalin and Epithalon for full immune coverage.
Bonomarlot (also designated A-20, CAS number not publicly assigned) is a Cytomax class bioregulator produced from the bone marrow of young calves, designed to support hematopoietic function. The theoretical basis comes from replicated Khavinson laboratory studies [1] showing that short peptides can enter cell nuclei and alter gene expression. It contains a mixture of short-chain peptides, typically 2 to 7 amino acids long, extracted and standardized at the St. Petersburg Institute of Bioregulation and Gerontology. The product ships as oral capsules containing 10 mg of peptide complex each. Bone marrow is where hematopoiesis happens. Red blood cells, white blood cells, platelets; they all originate from hematopoietic stem cells housed in that tissue. Age-related decline in marrow function contributes to immunosenescence, subclinical anemia, and reduced regenerative capacity. Bonomarlot's proposed job is to restore gene expression patterns in aging bone marrow cells by supplying tissue-specific peptide fragments that interact with DNA promoter regions. The honest assessment: zero Bonomarlot-specific clinical trials appear in PubMed. Community use is niche, with fewer than 50 indexed reports across English-language forums. Users follow manufacturer protocols closely and track results through CBC bloodwork rather than subjective effects. Pricing runs $135 to $190 per 60-capsule box from primary vendors.
The Khavinson bioregulator model proposes a specific chain of events. Small peptides survive gastric digestion because of their size. They cross the intestinal wall through PepT1 (SLC15A1) and LAT family transporters. Once in systemic circulation, they distribute to bone marrow tissue and enter target cells. Inside the nucleus, these peptides interact with nucleosomes and histone proteins at specific DNA sequences. Khavinson et al. [1] tested the related peptides AED, KED, and KE in human bone marrow mesenchymal stem cells. IGF1 expression increased 3.5 to 5.6-fold. FOXO1 and TERT gene activity also changed, both linked to cellular senescence pathways. A separate line of research supports bone marrow peptide signaling from a different angle. Petrov and Mikhailova identified endogenous regulatory hexapeptides (MP-1 and MP-2) produced by bone marrow cells themselves [3]. MP-1 stimulated antibody production up to 2.5-fold. MP-2 reversed tumor-induced T-lymphocyte suppression. These myelopeptides share structural homology with hemoglobin chain fragments, pointing to a conserved signaling function. Bonomarlot is theorized to supplement declining endogenous peptide signaling in aging marrow. Direct evidence for this product's intracellular activity has not been published.
No clinical trials specific to Bonomarlot exist in PubMed-indexed literature. Supporting evidence is class-level only: Khavinson et al. 2020 [1] demonstrated gene expression modulation by AED/KED/KE short peptides in human bone marrow MSCs. Myelopeptide research (Petrov et al., 9216250)[3] establishes that bone-marrow-derived hexapeptides have immunoregulatory activity. Direct hematopoietic benefit from oral Bonomarlot is undemonstrated in published controlled trials.
Khavinson et al. 2020 (PMID 32399807): gene expression modulation by short peptides in human bone marrow MSCs (class evidence; not Bonomarlot-specific)
Zero Bonomarlot-specific RCTs or PubMed-indexed clinical trials; all supporting data is extrapolated from related Khavinson peptides (AED/KED/KE) or myelopeptide pharmacology; oral short-peptide bioavailability estimated 10–30% with no Bonomarlot PK study; Russian-language clinical documentation not indexed in English databases
Niche use confined to the Khavinson bioregulator longevity community. Users follow manufacturer cycling protocols closely. Reported benefits center on immune resilience, perceived hematopoietic recovery post-illness, and the valued no-injection oral format. Zero dedicated Reddit threads indexed as of April 2026; community dataset is insufficient for robust sentiment analysis.
Community protocols mirror manufacturer (Khavinson Institute / Firma-Vita) dosing exactly. The underlying class-level science supports the short-peptide gene expression mechanism. Alignment exists on cycling rationale and dose range; divergence exists on evidence quality: the community operates on the broader Khavinson framework while Bonomarlot-specific trial data is absent.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Bonomarlot is an oral capsule product. No reconstitution, no bacteriostatic water, no syringes. Each capsule contains 10 mg of peptide complex. The standard protocol is straightforward: 2 capsules daily, 15 to 20 minutes before a meal, with a small amount of water. Swallow them whole. Don't chew or open the capsules. For a first-time user, the recommendation is a 30-day loading course before switching to 10-day maintenance courses every 3 to 6 months. If your CBC is normal and you're doing this preventively, the 10-day course twice yearly is sufficient. The thing most beginners miss: you won't feel anything. Bonomarlot produces no subjective effects. Get a CBC before your first course and again 4 weeks after finishing. Without baseline labs, you have no way to assess whether it's working. Ferritin, B12, and folate at baseline help rule out nutritional causes of low blood counts so you don't attribute improvements to a peptide when iron was the issue. Store capsules at room temperature (15 to 25 degrees Celsius). Keep them dry and out of direct sunlight. No refrigeration needed for sealed blister packs.
Standard Khavinson bioregulator protocol is 10-30 days on, then repeat every 3-6 months. A typical maintenance cycle is 2 capsules daily for 10 days, repeated twice per year. Therapeutic protocols may extend to 30 days. This cycling approach comes from the general Khavinson bioregulator framework: no Bonomarlot-specific cycling studies have been published. Some practitioners combine Bonomarlot with other bioregulators (Thymalin, Crystagen, Vladonix) in staggered cycles targeting different aspects of immune function.
Cycling in the Khavinson model is not driven by receptor desensitization or hormonal axis suppression. The proposed mechanism is epigenetic: short peptides modulate gene expression in bone marrow cells, and these expression changes persist for 3–6 months after the peptide is cleared. Continuous daily dosing adds no benefit once gene expression normalization is achieved: excess peptides are catabolized as amino acids. Cycling is intrinsic to the mechanism of action, not a safety precaution.
Or use the universal Peptide Calculator for any peptide.
Expected: Theoretical bone marrow gene expression normalization. No subjective effects expected within a single 10-day course; track via CBC before and 4 weeks after.
Monitor: CBC (RBC, hemoglobin, hematocrit, WBC differential, platelets) before course and 4 weeks after completion. Ferritin + B12 + folate at baseline to rule out nutritional causes.
Get a complete blood count with differential before starting your first course. This is your only objective way to track results.
Take 2 capsules (20 mg total) by mouth, 15 to 20 minutes before a meal. Use a small amount of water. Swallow whole without chewing.
For your first course, continue daily for 30 consecutive days (loading protocol). This uses one full 60-capsule box.
For maintenance courses after loading, take 2 capsules daily for 10 consecutive days. Repeat every 3 to 6 months.
The high-need protocol (under medical supervision only) increases to 2 capsules twice daily (40 mg/day) for 30 days, using two 60-capsule boxes per course.
Compare to your baseline. Look for trends in RBC, hemoglobin, hematocrit, WBC differential, and platelet count.
Store unopened blister packs at room temperature (15 to 25 degrees Celsius). Keep away from moisture and direct sunlight.
No reconstitution. No refrigeration for sealed product.
Thymus bioregulator: immune-longevity foundation stack. Thymalin targets T-lymphocyte maturation; Bonomarlot targets bone marrow hematopoiesis. Theoretically complementary organ-specific actions within the Khavinson multi-tissue system.
Staggered separate 10-day cycles: not simultaneous
Pineal bioregulator and telomere-targeted tetrapeptide. Combined with Thymalin + Bonomarlot as the classic Khavinson immune-longevity triple stack for anti-aging protocols.
Sequential or staggered courses; Epithalon typically injected while Bonomarlot is oral: compatible scheduling
Synthetic thymic tripeptide (Cytogen class). Some users add Crystagen for faster-acting thymic support while Bonomarlot provides longer-duration bone marrow support.
Thymic nonapeptide: additional immune modulation layer. Used alongside Bonomarlot for broader immune system coverage in the Khavinson multi-tissue framework.
Bone marrow-targeting peptides may interact unpredictably with myelosuppressive chemotherapy. No safety or interaction data exists; concurrent use poses undefined risk of altering myelosuppression depth or recovery kinetics.
Do not combineBonomarlot theoretically stimulates bone marrow immune output; counteracting immunosuppression in transplant recipients could precipitate rejection. Explicit contraindication.
Do not combineAdditive bone marrow stimulation is theoretically possible; no interaction data or safety monitoring guidance exists.
Concurrent bone marrow stimulation with hematopoietic growth factors is unstudied; potential for excessive or dysregulated hematopoietic activation.
Pricing updated 2026-04-09
The most serious consideration with Bonomarlot is what it might do in people who should not take it, not what it does in healthy users. Active hematologic malignancies (leukemia, lymphoma, myeloma) are an explicit contraindication. Stimulating bone marrow activity in the presence of malignant hematopoietic cells could accelerate disease progression; no safety data exists for this scenario. Organ transplant recipients on immunosuppressive therapy face a related concern. Bonomarlot theoretically stimulates bone marrow immune output. Counteracting immunosuppression with cyclosporine or tacrolimus could precipitate graft rejection. This interaction is theoretical but the stakes make it a hard avoid. For healthy adults following standard protocols, the side effect profile appears mild based on limited user reports. Occasional gastrointestinal discomfort (nausea, bloating) is possible with any oral peptide product. These symptoms, when reported, typically resolve by day 2 or 3 of a course. Allergic reactions are theoretically possible. Bonomarlot is extracted from bovine bone marrow tissue. Anyone with a known allergy to bovine-derived products should not use it. Excipient composition varies across vendors: RuPharma's formulation contains lactose and Tween-80, while PeptidesAmerica uses carrageenan and HPMC. Users with excipient sensitivities should verify the ingredient list before ordering. The human safety dataset is effectively zero for Bonomarlot specifically. No controlled tolerability study has been published in indexed literature. Most safety inferences come from the broader Khavinson bioregulator program, where adverse event rates across multiple products have been low in Russian-language clinical documentation. Pregnancy and breastfeeding are contraindicated. No reproductive safety data exists. Children under 18 should not use this product; no pediatric dosing or safety information is available. Concurrent use with chemotherapy agents poses undefined risk. Bone marrow-targeting peptides could alter myelosuppression depth or recovery kinetics in unpredictable ways. EPO, darbepoetin, filgrastim, and sargramostim carry similar theoretical interaction concerns due to additive bone marrow stimulation. Stop use and consult a physician if you develop urticaria, persistent GI distress, or worsening CBC trends on repeat testing.
Verify Bonomarlot dosing and safety with a second opinion
Bovine-derived multi-peptide extract with no standardized Western batch-testing benchmarks. No publicly available COAs from primary vendors. Significant excipient variation across manufacturers (lactose + Tween-80 at RuPharma; carrageenan + HPMC at PeptidesAmerica; MCC + calcium stearate at DN Lab) creates undisclosed risk for users with intolerance to these excipients. Secondary-market pricing at $85 (Ballwool) vs $135–190 (primary vendors) raises authenticity and cold-chain concerns.
| Test | When | Target |
|---|---|---|
| Complete Blood Count (CBC with differential) | Before each course and 4 weeks after course completion | Age-appropriate normal reference ranges; any sustained upward trend in previously suppressed markers (hemoglobin, RBC) is interpreted as a positive signal |
| Ferritin + Serum B12 + Folate | Baseline before first course; reassess if CBC shows no improvement after 2 cycles | — |
| Serum calcium + phosphorus | Baseline: only relevant if stacking with Bonothyrk (parathyroid bioregulator) | — |
Primary efficacy proxy for bone marrow function. Tracks RBC count, hemoglobin, hematocrit, WBC differential, and platelet count. No direct commercial assay exists for the A-20 peptide complex.
Nutritional causes of hematopoietic deficiency (iron deficiency, B12/folate deficiency) must be excluded and corrected before attributing CBC changes to Bonomarlot
Concurrent bone marrow and parathyroid bioregulator use introduces calcium homeostasis monitoring requirements; not required for Bonomarlot alone
Beginning of the standard 10-day course. Peptides are being absorbed and theoretically reaching bone marrow tissue. No noticeable changes expected during this initial phase. Mild GI adjustment is possible but uncommon.
Completion of standard maintenance course. According to Khavinson bioregulator theory, tissue-specific gene expression modulation is accumulating. Most users won't notice overt changes during a short course. Some report a general sense of improved energy or wellbeing, though this is anecdotal.
Extended therapeutic courses may produce more pronounced effects on bone marrow function. Blood panel changes (CBC, differential) might become detectable in this window, though no published data confirms this for Bonomarlot specifically.
The bioregulator model proposes that gene expression changes persist beyond the active dosing period. Effects are thought to build cumulatively over multiple courses. Repeat bloodwork before the next course to track trends in blood cell counts and immune markers.
Days 1 through 5 (absorption phase): Short peptides (2 to 7 amino acids) are absorbing through PepT1 and LAT intestinal transporters. The theory says they distribute to bone marrow via systemic circulation. Nothing detectable happens at this stage. Some users report mild GI adjustment (bloating, light nausea) that clears by day 2 or 3. Days 6 through 10 (course completion for standard maintenance): Per the Khavinson model, epigenetic gene expression modulation is accumulating. No acute markers are expected; the mechanism is slow by design. Most users report no perceptible change through a 10-day course. Occasional anecdotal "wellbeing" improvements surface but can't be attributed to a specific mechanism. Days 10 through 30 (extended loading course): Greater cumulative peptide exposure. CBC changes are theoretically detectable toward the end of a 30-day course in individuals with documented hematopoietic suppression. No published data from Bonomarlot specifically confirms this. Some users report improved energy or reduced fatigue at weeks 3 to 4. Khavinson practitioners have noted anecdotal upward trends in RBC or hemoglobin. 1 to 6 months post-course (residual effect window): The Khavinson model proposes that epigenetic changes persist 3 to 6 months after dosing ends. Cumulative benefit is supposed to compound over multiple annual cycles, but no RCT validates this timeline. Most attributed benefits occur in this window: immune resilience, fewer infections, sustained energy. CBC trends are most informative at the 4-week post-course draw rather than during active dosing.
Short peptides (2–7 AA) absorbing via PepT1/LAT intestinal transporters; theoretical distribution to bone marrow tissue via systemic circulation. No detectable markers expected at this stage.
No reported subjective effects during the first week. Occasional mild GI adjustment (bloating, mild nausea) resolving by day 2–3.
Epigenetic gene expression modulation proposed to be accumulating at this stage per Khavinson model. No acute-phase markers expected. Effect onset is mechanistically slow.
No perceptible change reported by most users through a standard 10-day course. Occasional anecdotal "wellbeing" improvement, not attributed to a specific mechanism.
Greater cumulative peptide exposure. CBC changes theoretically detectable toward the end of a 30-day course in individuals with documented hematopoietic suppression; no Bonomarlot-specific published data confirms this.
Some users report improved energy or reduced fatigue at weeks 3–4. No systematic data. CBC improvements reported anecdotally by Khavinson practitioners: typically RBC or hemoglobin upward trend.
Khavinson model proposes epigenetic gene expression changes persist 3–6 months after dosing ends. Cumulative benefit proposed to compound over multiple annual cycles, but no Bonomarlot RCT validates this timeline.
Most attributed benefits occur in this post-course window: immune resilience (fewer infections), sustained energy. CBC trends, when tracked, are most informative at the 4-week post-course draw rather than during active dosing.
Source: No published pharmacokinetic data exists for Bonomarlot specifically. The estimated half-life is extrapolated from general short peptide (2-7 amino acid) oral pharmacokinetics. Di- and tripeptides absorbed via PepT1 transporters typically have plasma half-lives of 1-3 hours before proteolytic degradation. This estimate carries very low confidence and should not be used for clinical decision-making.
Loading the interactive decay curve.
Bonomarlot is classified as a dietary supplement in Russia and several CIS countries, where it is manufactured by Firma-Vita under the Khavinson Institute licensee framework. It is not FDA-approved or regulated as a drug in the United States. In the U.S., Bonomarlot occupies the grey area common to imported bioregulators. It is available through specialty vendors (Qi Supplements, RuPharma, PeptidesAmerica, CosmicNootropic) who import it as a dietary supplement or for personal use. No DEA scheduling applies. No WADA prohibition exists for this product class. The product has no assigned CAS number in Western chemical databases. No NDA, IND, or formal regulatory application has been filed with any Western drug agency. This content is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before starting any peptide protocol. Peptide Schedule does not sell peptides or endorse specific suppliers.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
